血清咖啡因及其代谢物是早期帕金森病的可靠生物标志物
该研究采用液相色谱-质谱法检测108例帕金森病患者和31例年龄匹配健康对照的血清咖啡因及其11种代谢物水平,并筛查咖啡因相关基因突变。结果显示,即使早期帕金森病患者,血清咖啡因及9种下游代谢物水平也显著降低,且与总咖啡因摄入量或疾病严重程度无关。ROC曲线分析表明血清咖啡因及代谢物谱可作为早期帕金森病的潜在诊断生物标志物。
要点
- 早期帕金森病患者血清咖啡因及9种代谢物水平显著降低
- 降低与总咖啡因摄入量及疾病严重程度无关
- 血清咖啡因及代谢物谱可作为早期帕金森病诊断生物标志物
核心结论
- 绝对较低的咖啡因及其代谢物谱是早期帕金森病有前景的诊断生物标志物。
- 这与流行病学和实验研究揭示的咖啡因神经保护作用一致。
研究设计与样本
- 研究纳入108例帕金森病患者和31例年龄匹配健康对照,采用液相色谱-质谱法检测血清咖啡因及其11种代谢物水平。
- 通过直接测序筛查咖啡因相关基因突变。
主要发现
- 即使早期帕金森病患者,血清咖啡因及9种下游代谢物水平也显著降低,且与总咖啡因摄入量或疾病严重程度无关。
- 未检测到CYP1A2或CYP2E1基因显著变异与对照相比。
- 有运动并发症的帕金森病患者咖啡因浓度显著低于无运动并发症者。
- 未发现疾病严重程度与ADORA2A基因单核苷酸变异之间的关联。
- ROC曲线分析将血清咖啡因及代谢物水平谱确定为潜在诊断生物标志物。
关键数值与推荐
- 本研究提供III级证据表明血清咖啡因及其代谢物水平降低可识别帕金森病患者。
临床怎么用
- 血清咖啡因及其代谢物谱有望作为早期帕金森病的诊断生物标志物,辅助临床识别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the kinetics and metabolism of caffeine in serum from patients with Parkinson disease (PD) and controls using liquid chromatography-mass spectrometry. METHODS: Levels of caffeine and its 11 metabolites in serum from 108 patients with PD and 31 age-matched healthy controls were examined by liquid chromatography-mass spectrometry. Mutations in caffeine-associated genes were screened by direct sequencing. RESULTS: Serum levels of caffeine and 9 of its downstream metabolites were significantly decreased even in patients with early PD, unrelated to total caffeine intake or disease severity. No significant genetic variations in CYP1A2 or CYP2E1, encoding cytochrome P450 enzymes primarily involved in metabolizing caffeine in humans, were detected compared with controls. Likewise, caffeine concentrations in patients with PD with motor complications were significantly decreased compared with those without motor complications. No associations between disease severity and single nucleotide variants of the ADORA2A gene encoding adenosine 2A receptor were detected, implying a dissociation of receptor sensitivity changes and phenotype. The profile of serum caffeine and metabolite levels was identified as a potential diagnostic biomarker by receiver operating characteristic curve analysis. CONCLUSION: Absolute lower levels of caffeine and caffeine metabolite profiles are promising diagnostic biomarkers for early PD. This is consistent with the neuroprotective effect of caffeine previously revealed by epidemiologic and experimental studies. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that decreased serum levels of caffeine and its metabolites identify patients with PD.
引用
- Fujimaki M, Saiki S, Li Y, et al. Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology. 2018. PMID: 29298852. doi:10.1212/WNL.0000000000004888
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。